At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,027 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TRANSFORM - Observational Cohort Study of Aranesp Use in EU Haemodialysis Patients Switched From Mircera
In Brief
An observational study for Anemia. Completed, enrolled 1,027 participants across 32 sites in 7 countries.
Detailed Summary
To describe the time course of hemoglobin concentration in EU hemodialysis patients switched from methoxy polyethylene glycol-epoetin beta (PEG epoetin beta; Mircera) to darbepoetin alfa (Aranesp).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesBelgium, France, Germany, Greece, Netherlands, Spain, Switzerland
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
Primary CompletionJun 2013
Study CompletionJul 2013
First PostedNov 2013
TodayJul 2026
First PostedNov 28, 2013
Enrollment StartAug 1, 2012
Primary CompletionJun 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.6 years ago